GLP-1 Receptor Agonist Cardiovascular Evidence: Meta-Analysis
This GLP-1 receptor agonist cardiovascular meta-analysis synthesizes data from major trials demonstrating reduced cardiovascular events. The evidence supports GLP-1 receptor agonists as cardioprotective agents beyond weight loss. Clinicians can use this…
GLP-1 Receptor Agonist Evidence: Muscle Loss Risks
GLP-1 Clinical Relevance #47Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Systematic ReviewMeta-AnalysisObesityMuscle Mass…
Efficacy of high-definition transcranial direct current stimulation on craving in substance use disorders: a systematic review and meta-analysis.
High-definition transcranial direct current stimulation is a promising noninvasive method for reducing craving in substance use disorders. This systematic review and meta-analysis evaluates its efficacy. The focus on craving highlights its potential role…
Cannabis Use and Trauma-Focused Treatment for PTSD: Meta-Analysis
Cannabis trauma-focused treatment PTSD research reveals that cannabis use does not diminish the effectiveness of evidence-based PTSD therapies. Individuals with PTSD and substance use disorders benefit from trauma-focused treatments regardless of…
`Cannabinoid Clinical Trials for Mental and Substance Use Disorders`
Clinical Takeaway Randomized controlled trial evidence reviewed in this meta-analysis does not firmly establish cannabinoids as effective or consistently safe treatments for mental health or substance use disorders. Clinicians should interpret current…
GLP-1 Receptor Agonist Randomized Trial: Muscle Loss Risk
GLP-1 receptor agonist muscle mass loss is a significant concern in obesity treatment. Randomized trials show these agents can cause disproportionate lean muscle loss. Clinicians should emphasize muscle preservation strategies alongside therapy.
Comparing Muscle Loss Risks with GLP-1 Receptor Agonists
GLP-1 receptor agonist muscle loss compared to other weight loss methods reveals important risks. Semaglutide and liraglutide cause significant weight loss but may reduce lean muscle mass. Understanding these risks helps optimize treatment and preserve…
Over 70% Of Studies Back Medical Cannabis In Cancer Treatment: A Sweeping Meta-Analysis
A medical cannabis cancer treatment meta-analysis found that over 70% of studies demonstrate clinical benefit. This meta-analysis supports cannabis use in oncology for symptom management. The findings highlight cannabis's role in cancer supportive care.
Review of Cannabinoid Clinical Trials for Anxiety and Tourette
Cannabinoid clinical trials anxiety research reveals measurable reductions in anxiety symptoms across various disorders. Evidence supports modest but meaningful benefits, especially for generalized anxiety and Tourette syndrome. These findings highlight…
GLP-1 Receptor Agonist Evidence: 20% Heart Attack Risk Drop
GLP-1 receptor agonist cardiovascular outcomes safety data reveal a 20% reduction in heart attack risk. Semaglutide's cardioprotective effects extend beyond glucose control. Medicare Part D coverage expansion in 2026 improves access for high-risk…